DOES BODY FAT MASS DEFINE SURVIVAL IN PATIENTS STARTING PERITONEAL DIALYSIS?
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Soo Jeong | - |
dc.contributor.author | Kim, Eun Jung | - |
dc.contributor.author | Park, Moo Yong | - |
dc.contributor.author | Kim, Jin Kuk | - |
dc.contributor.author | Hwang, Seung Duk | - |
dc.date.accessioned | 2021-08-11T22:45:31Z | - |
dc.date.available | 2021-08-11T22:45:31Z | - |
dc.date.issued | 2014-06 | - |
dc.identifier.issn | 0896-8608 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/12151 | - |
dc.description.abstract | Background and Aims: Peritoneal dialysis (PD) is characterized by a gain in fat mass. Unlike subcutaneous fat, visceral fat is associated with metabolic syndrome and survival. We prospectively examined whether visceral or subcutaneous fat could predict outcome in patients undergoing PD. Methods: We studied 117 new patients (57 men) undergoing PD between February 2006 and November 2011. Baseline body composition was measured on computed tomograms. Visceral obesity was defined as a visceral fat area exceeding 100 cm(2), and subcutaneous obesity, as a subcutaneous fat area exceeding 130 cm(2). Results: Among the 117 patients, 37 and 29 were diagnosed with visceral and subcutaneous obesity respectively. Visceral and subcutaneous obesity were both present in 21 patients. In the study population, the 1-year and 5-year survival rates were 94% and 59%. The rates of peritonitis and exit-infection were 0.31 and 0.14 episodes per patient-year. Mortality was greater in patients with visceral obesity than in those without visceral obesity (p = 0.005). Visceral obesity had no influence on peritonitis and exit-infection rates. Subcutaneous obesity was associated neither with survival nor with peritonitis or exit-site infection. In a multivariate Cox regression analysis, visceral obesity was not a risk factor for poor outcome. Conclusions: Increased visceral fat at PD initiation is not an independent predictor of poor survival. Any impact of visceral or subcutaneous fat mass on outcomes in patients undergoing PD would be better defined by larger, long-term studies. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Multimed, Inc. | - |
dc.title | DOES BODY FAT MASS DEFINE SURVIVAL IN PATIENTS STARTING PERITONEAL DIALYSIS? | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.3747/pdi.2011.00152 | - |
dc.identifier.scopusid | 2-s2.0-84925883223 | - |
dc.identifier.wosid | 000338514300010 | - |
dc.identifier.bibliographicCitation | Peritoneal Dialysis International, v.34, no.4, pp 376 - 382 | - |
dc.citation.title | Peritoneal Dialysis International | - |
dc.citation.volume | 34 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 376 | - |
dc.citation.endPage | 382 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Urology & Nephrology | - |
dc.relation.journalWebOfScienceCategory | Urology & Nephrology | - |
dc.subject.keywordPlus | HEMODIALYSIS-PATIENTS | - |
dc.subject.keywordPlus | VISCERAL FAT | - |
dc.subject.keywordPlus | INSULIN-RESISTANCE | - |
dc.subject.keywordPlus | NUTRITIONAL-STATUS | - |
dc.subject.keywordPlus | RISK-FACTOR | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | OBESITY | - |
dc.subject.keywordPlus | CAPD | - |
dc.subject.keywordPlus | ATHEROSCLEROSIS | - |
dc.subject.keywordPlus | INFLAMMATION | - |
dc.subject.keywordAuthor | Body composition | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.